



At Sun Pharma, as part of our core strategy, we strive to emphasise on sustainability, operational resilience and workforce agility to revitalise our business activities for the next phase of growth. In these extraordinary times, Sun Pharma remains strong in its commitment to uplift communities and enhance access to affordable and transformative healthcare for all."

Dilip Shanghvi
Managing Director

Dear Stakeholders,

It gives me immense pleasure to welcome you to our maiden Sustainability Report FY21. This report presents an overview of our approach, key initiatives and performance across economic, social and environmental parameters. We publish this Report amid an unprecedented and evolving pandemic, which continues to impact our stakeholders globally. Businesses worldwide are at crossroads, now more than ever, to address the deep economic and social consequences of the pandemic. As they resume operations and recover from the far-reaching impact of the pandemic, the global community resonates with the idea of building back stronger. At Sun Pharma, as part of our core strategy, we strive to emphasise on sustainability, operational resilience and workforce agility to revitalise our business for the next phase of growth. In these extraordinary times, we remain strong in our commitment to uplift communities and enhance access to affordable and transformative healthcare for all.

GRI 102-14

A continuing legacy of care: Our sustainability driven approach

Our business is built on a legacy rooted in caring for people, communities and the planet. In our quest to augment the accessibility and affordability of healthcare, we aim to establish benchmarks for enhanced efficiency across our business activities with a renewed commitment to safeguarding the environment and our communities.



We revolutionised our approach to sustainability, and have identified our sustainability levers and aspirations detailed on [page 20](#)

Enabling value creation: Our economic performance

We are the 4th largest specialty generic pharmaceutical company in the world with global consolidated revenues of ₹334,981 Million in FY21. We have a strong presence across 100+ countries in branded and generic markets. Staying true to our 'Sunology', we enhance the development of differentiated generics and innovative specialty products through consistent R&D investments of over ~₹199 Billion till date. While we continue to build our product pipeline, we do so with a strong commitment to patient safety and product quality.

We are the first Indian pharmaceutical company to have implemented global pharmacovigilance systems and processes since 2005, with a dedicated and diverse global pharmacovigilance team. Our pharmacovigilance unit along with our established Quality Management System, enable us to keep patient safety at the heart of our business activities. We have established a Center of Excellence (CoE) that encourages the adoption of innovative technologies across varied functions. We also focus on responsible procurement practices, ensuring efficacious monitoring of supply chain risks and the implementation of robust mitigation measures. We swiftly adapted to the changing dynamics related to the global COVID-19 pandemic, and ensured continuity of our manufacturing and supply chain, in order to service the needs of patients and healthcare providers.

Stronger together: Our workforce

Our employees have been at the forefront of enabling our business growth and creating differentiated strategic levers for our company. I take pride in our diverse, passionate and dedicated workforce that consists of a rich blend of talents and cultures working together towards shared goals. Through our training and development programmes, we progressively instill values that enable a conducive, proactive and growth-oriented mindset in our workforce. In FY21, we imparted over 955,000 hours of training encompassing both, technical and soft skill development. We lay utmost importance on the all-round well-being and safety of our employees. Most of our facilities are ISO 45001:2018 certified with stringent measures in place to ensure the safety of employees. I would like to take this opportunity to thank our employees at Sun Pharma for their unwavering commitment and going above and beyond, during the pandemic to serve our stakeholders.

Enabling positive social outcomes: Our holistic community development programmes

A common thread in our vision is to achieve a resilient and secure society. We continue to strengthen our relationships with stakeholders to enhance our outreach and support

our corporate citizenship initiatives. Our activities focus on healthcare, education, water and sanitation as well as environment conservation, among others. Our Corporate Social Responsibility (CSR) vision and objectives embed sustainable interventions across our programmes to ensure holistic development of underserved communities with a CSR expenditure of ₹575 Million in FY21. Furthermore, our CSR vision is aligned with the United Nations Sustainable Development Goals (UN SDGs). We have prioritised seven SDGs and ensure that all our CSR activities deliver impact in line with the SDGs. We went beyond our focus areas and worked relentlessly to support communities to effectively respond to the COVID-19 pandemic. We also supported the healthcare needs of our government through the donation of medicines, hand sanitisers and PPE kits. We would like to extend our heartfelt gratitude to our NGO partners and stakeholders who overcame challenges to support communities in the battle against the pandemic and who continue to enhance their efforts to develop a holistic and sustainable community.

Preserving value for future generations: Our environmental performance

At Sun Pharma, we believe that enterprises globally share the responsibility of creating value for stakeholders in a manner that supports the ability of future generations to create value. To reinforce our commitment to global climate action, we have pledged to reduce our Greenhouse Gas (GHG) emissions in India's 2nd CEO Forum on Climate Change. We are among the 24 signatories who pledged to make contributions to develop industrial resilience and help India meet its targets for the Paris Agreement. In FY21, ~38% of our energy requirements were met through renewable sources. Waste and water management are also vital aspects of our environmental management plan. We have employed co-processing and recycling based initiatives towards minimising waste to landfill. Additionally, ~86% of our manufacturing facilities are Zero Liquid Discharge (ZLD).

We continuously monitor and measure our energy and water usage and efforts are ongoing to improve the consumption parameters.

Paving the way for shared growth

As we expand our sphere of positive social impact and serve more markets, we remain steadfast in embedding the principles of sustainability across our value chain. We will continue to ensure affordability and accessibility to transformative therapeutic solutions through safe and high quality products. Our people, patients and other stakeholders will remain at the crux of our corporate purpose as we look forward to creating a sustainable growth trajectory that enables a shared future for all.

Warm regards,

Dilip Shanghvi
Managing Director